The Crisis
The Betrayal of Numbers
Why raising hormones doesn't save lives
Key Moment
The cruel irony: MK-677 successfully raised growth hormone to youthful levels, but didn't make people stronger, faster, or functionally better. The numbers looked good. The lives didn't change.
The 2008 Nass trial had a secret hidden in its footnotes. Yes, MK-677 increased lean muscle mass by 1.1 kilograms compared to placebo. That sounds good. But the elderly people taking MK-677 didn't get any stronger. They couldn't walk further. They didn't feel better. Their quality of life didn't improve. Their muscle strength didn't increase. This was the dark truth: you can raise growth hormone to youthful levels and still not improve what matters — what people can actually do.
There was something else in those trial results that alarmed doctors. Fasting blood glucose increased by about 5 mg/dL in the MK-677 group. Insulin sensitivity declined. This meant your cells weren't responding to insulin as well. These are early warning signs of diabetes. For elderly patients already at risk for type 2 diabetes, this was concerning. A pill that helped your bones but increased your diabetes risk wasn't a fair trade.
MK-677 also increased appetite. This made sense — it was hitting the ghrelin sensor, which controls hunger. For young people trying to gain muscle, more appetite was useful. But for elderly people trying to maintain their weight, increased hunger could lead to overeating and weight gain. Other side effects included water retention and edema (swelling in the feet and legs). Patients complained of muscle pain and joint discomfort.
In 2008, another major trial brought crushing disappointment. Sevigny and colleagues tested MK-677 in patients with Alzheimer's disease. If raising growth hormone could improve brain function and muscle mass, why not test it in patients losing both due to dementia? The trial failed completely. MK-677 did not slow the progression of Alzheimer's disease. It did not improve cognitive function. It did not help patients maintain brain health. The hormone boost simply didn't translate to the brain improvements that researchers had hoped for.
Merck had already walked away from MK-677 in 1999. The company had decided the benefits didn't justify the risks and side effects. But the compound didn't disappear. It escaped into a different world. Bodybuilders discovered MK-677. Biohackers read the trial data. The underground market exploded. Online forums discussed dosing protocols. People ordered MK-677 from overseas suppliers in unlabeled vials. WADA, the World Anti-Doping Agency, banned MK-677 in competitive sports — both during competitions and outside competitions. The FDA started warning about adulterated dietary supplements containing hidden ibutamoren. Counterfeit products flooded the market.
A compound designed in Merck's pristine laboratories, tested with scientific rigor, was now being sold in unlabeled bottles on the internet. Nobody knew the purity. Nobody knew the dosage. The long-term consequences were unknown. Cancer risk was a concern — elevated IGF-1 can promote tumor growth in some people. Merck's failed dream had become a biohacking experiment with unknown endpoints.